Project description:This SuperSeries is composed of the following subset Series: GSE25690: Global analysis of mRNA expression in prospectively purified human prostate orthotopic xenograft tumor cells with varying S/TFE. GSE25691: Global analysis of miRNA expression in prospectively purified human prostate orthotopic xenograft tumor cells with varying S/TFE. Refer to individual Series
Project description:Human prostate CWR22 OT-tumor cells were prospectively purified for expression of various stem cell markers (TRA-1-60/CD151/CD166/EpCAM/CD44/α2-Integrin). Unsorted total tumor cells or the additional marker positive cells that do not manifest stem-like characteristics were used as control. All these cells were subjected to molecular profiling of total RNA expression and the fold change data are tabulated according to S/TFE of the purified cells in relation to their control. Notes: Low S/TFE = Low sphere and tumor forming efficiency; Moderate S/TFE = Moderate sphere and tumor forming efficiency; High S/TFE = High sphere and tumor forming efficiency; FDR* = False Discovery Rate; FC = Fold Change; Signal = Average Expression Signal Level. Low-S/TFE, Moderate S/TFE, High S/TFE data sets were compared to No S/TFE control sets
Project description:Human prostate CWR22 OT-tumor cells were prospectively purified for expression of various stem cell markers (TRA-1-60/CD151/CD166/EpCAM/CD44/α2-Integrin). Unsorted total tumor cells or the additional marker positive cells that do not manifest stem-like characteristics were used as control. All these cells were subjected to molecular profiling of total RNA expression and the fold change data are tabulated according to S/TFE of the purified cells in relation to their control. Notes: Low S/TFE = Low sphere and tumor forming efficiency; Moderate S/TFE = Moderate sphere and tumor forming efficiency; High S/TFE = High sphere and tumor forming efficiency; FDR* = False Discovery Rate; FC = Fold Change; Signal = Average Expression Signal Level. Low-S/TFE, Moderate S/TFE, High S/TFE data sets were compared to No S/TFE control sets
Project description:Human prostate CWR22 OT-tumor cells were prospectively purified for expression of various stem cell markers (TRA-1-60/CD151/CD166/EpCAM/CD44/α2-Integrin). Unsorted total tumor cells or the additional marker positive cells that do not manifest stem-like characteristics were used as control. All these cells were subjected to molecular profiling of total RNA expression and the fold change data are tabulated according to S/TFE of the purified cells in relation to their control. Notes: Low S/TFE = Low sphere and tumor forming efficiency; Moderate S/TFE = Moderate sphere and tumor forming efficiency; High S/TFE = High sphere and tumor forming efficiency; FDR* = False Discovery Rate; FC = Fold Change; Signal = Average Expression Signal Level.
Project description:Human prostate CWR22 OT-tumor cells were prospectively purified for expression of various stem cell markers (TRA-1-60/CD151/CD166/EpCAM/CD44/α2-Integrin). Unsorted total tumor cells or the additional marker positive cells that do not manifest stem-like characteristics were used as control. All these cells were subjected to molecular profiling of total RNA expression and the fold change data are tabulated according to S/TFE of the purified cells in relation to their control. Notes: Low S/TFE = Low sphere and tumor forming efficiency; Moderate S/TFE = Moderate sphere and tumor forming efficiency; High S/TFE = High sphere and tumor forming efficiency; FDR* = False Discovery Rate; FC = Fold Change; Signal = Average Expression Signal Level.
Project description:We perform RNA-seq on matched orthotopic murine primary and metastatic prostate cancer samples to identify differential gene expressions RNA-seq was performed on orthotopic murine primary and metastatic tumor samples using Illumina Hi-Seq 2000 platform
Project description:Frequent discrepancies between preclinical and clinical results of anti-cancer agents demand a reliable translational platform that can precisely recapitulate the biology of human cancers. Another critical unmet need is the ability to predict therapeutic responses for individual patients. Toward this goal, we have established a library of orthotopic glioblastoma (GBM) xenograft models using surgical samples of GBM patients. These patient-specific GBM xenograft tumors recapitulate histopathological properties and maintain genomic characteristics of parental GBMs in situ. Furthermore, in vivo irradiation, chemotherapy, and targeted therapy of these xenograft tumors mimic the treatment response of parental GBMs. We also found that establishment of orthotopic xenograft models portends poor prognosis of GBM patients and identified the gene signatures and pathways signatures associated with the clinical aggressiveness of GBMs. Together, the patient-specific orthotopic GBM xenograft library represent the preclinically and clinically valuable “patient tumor’s phenocopy” that represents molecular and functional heterogeneity of GBMs. aCGH experiments were performed for a human glioblastoma tissue (sample ID: PC-NS08-559) and the matching xenograft tumor tissue using the Agilent Human Whole Genome CGH 244K microarray according to manufacturer's protocol (2-color).
